Portal de Periódicos da CAPES

The Liver Toxicity Biomarker Study: Phase I Design and Preliminary Results

2009; SAGE Publishing; Volume: 37; Issue: 1 Linguagem: Inglês

10.1177/0192623308329287

1533-1601

Robert McBurney, Wade Hines, Linda S. Von Tungeln, Laura K. Schnackenberg, Richard D. Beger, Carrie L. Moland, Tao Han, James C. Fuscoe, Ching‐Wei Chang, James J. Chen, Zhenqiang Su, Xiaohui Fan, WEIDA TONG, Shelagh A. Booth, Raji Balasubramanian, Paul Courchesne, J. M. Campbell, Armin Graber, Yu Cheng Guo, Péter Juhász, Tricin Y. Li, Moira D. Lynch, Nicole Morel, Thomas N. Plasterer, Edward J. Takach, Chenhui Zeng, Frederick A. Beland,

Pharmacogenetics and Drug Metabolism

Drug-induced liver injury (DILI) is the primary adverse event that results in withdrawal of drugs from the market and a frequent reason for the failure of drug candidates in development. The Liver Toxicity Biomarker Study (LTBS) is an innovative approach to investigate DILI because it compares molecular events produced in vivo by compound pairs that (a) are similar in structure and mechanism of action, (b) are associated with few or no signs of liver toxicity in preclinical studies, and (c) show marked differences in hepatotoxic potential. The LTBS is a collaborative preclinical research effort in molecular systems toxicology between the National Center for Toxicological Research and BG Medicine, Inc., and is supported by seven pharmaceutical companies and three technology providers. In phase I of the LTBS, entacapone and tolcapone were studied in rats to provide results and information that will form the foundation for the design and implementation of phase II. Molecular analysis of the rat liver and plasma samples combined with statistical analyses of the resulting datasets yielded marker analytes, illustrating the value of the broad-spectrum, molecular systems analysis approach to studying pharmacological or toxicological effects.